|
Ubatan HIV dan Ibola tidak dibuktikan berkesan dan kita boleh ketegorikan ianya sebagai mitos sehingga hari ini.
mitos jer rupa nya ....
|
|
|
|
|
|
|
|
mitos saja umpama mitos minum air panas
we are doomed
were going to die
|
|
|
|
|
|
|
|
Edited by borrow at 23-3-2020 08:04 AM
What are the prospects for a Covid-19 treatment?
The anti-malaria drug: chloroquine
Chloroquine is a cheap, widely available drug that has been routinely used since 1945 against malaria and other conditions and can be safely taken by pregnant women and children. Lab studies found the antiviral drug was effective against the coronavirus, at least in a petri dish, and results from a small French study in 24 patients, announced this week, suggested that it could quicken recovery.
Doctors said 25% of patients who received the drug tested positive for the virus after six days, compared with 90% of those who did not receive it. Chloroquine and a related drug, hydroxychloroquine, are among the four treatments tested in an international clinical trial, announced on Wednesday by the World Health Organization (WHO), and the UK has added chloroquine to its list of medicines under export controls.
The HIV treatment drug: Kaletra
Kaletra is a combination of two antiviral medicines, lopinavir and ritonavir, normally used to treat HIV, which lab studies suggested held promise as a potential Covid-19 treatment. However, these hopes suffered a significant setback this week with one of the first major studies of 200 seriously ill patients from China finding no benefit. The study is not the end of the road: it is possible that the drug could be effective if given earlier on, or to less severely ill patients. The WHO has included Kaletra in a major multi-country trial launched this week.
The anti-flu drug: favipiravir
The Japanese flu drug, made by a subsidiary of Fujifilm, has created a stir by more than halving the time that people with Covid-19 test positive for the virus. A Chinese trial in 340 people showed that the virus tended to be cleared in four days in those who received the drug, versus 11 days in those who went without. Chest scans supported the findings, revealing less damage in those who took the drug. But the antiviral, also known as Avigan, may need to be given before virus levels peak in the body. A Japanese health official told the Mainichi Shimbun newspaper that it did not appear to work as well in severely ill people, in whom the virus had had more time to replicate.
The Ebola drug: remdesivir
Remdesivir was originally developed as an Ebola treatment, but the drug has emerged as a frontrunner among potential antiviral drugs to combat Covid-19. The enthusiasm comes from studies that show that it works against Sars and Mers, two other coronaviruses that are more lethal but less transmissible. The drug works by shutting off the virus’s ability to replicate itself inside cells. This means it is most likely to be effective when a person has just caught the bug and the virus is still reproducing in the upper respiratory tract. One reason for caution is that early data suggest people may already have high levels of the virus when they start showing symptoms. Multiple trials are under way to evaluate remdesivir in China, the US and Asia, with the first results due in April.
Antibody therapies
Doctors in China have treated some critically ill patients with the blood plasma of recovered patients, an approach that dates back to the Spanish flu pandemic of 1918. The logic is that the blood should contain antibodies to help fight off infection. Downsides include the difficulties of scaling up the method for widespread use, the risk of transmitting other diseases and that the relevant antibodies are only present in small amounts, so the treatment, if effective at all, is far from optimal. A number of teams, including the US company Regeneron, are working on the hi-tech equivalent of serum therapy. Regeneron says it is a few weeks away from identifying two powerful antibodies that protect against Covid-19, which it will then manufacture synthetically and turn into a therapeutic cocktail, with a view to starting human trials in the summer. If successful, an antibody therapy could be used as both a treatment and a prophylactic to protect health workers and other high-risk groups.
Interferon beta
The UK biotech firm Synairgen has been given fast-track approval to trial a lung-disease drug in Covid-19 sufferers. The compound, interferon beta, forms part of the lung’s natural defence system against viruses and was originally developed for patients with chronic obstructive pulmonary disorder, or COPD. The hope is that administering interferon beta boosts the body’s ability to fight the virus, especially in those who have weakened immune systems. It was identified in February by the WHO as the only therapy in phase-2 trials that can be inhaled, meaning patients can administer it themselves through a small battery-operated nebulise
https://www.theguardian.com/scie ... irus-drugs-vaccines
|
|
|
|
|
|
|
|
suka baca thread seperti ini ...
Terimakasih
|
|
|
|
|
|
|
|
gedik sungguh
|
|
|
|
|
|
|
|
Interferon ada side effects bètter try interferon inducer... |
|
|
|
|
|
|
|
im4me replied at 23-3-2020 08:59 AM
Rasanya kalau untuk public susah nak produce interferon ni dan kalau guna untuk jagkitan tahap awa ...
Interferon mmg susah nak mass produce, tapi intrferon inducer readily available, tak der side effects dan versatile for any version of viruses tak yah tunggu 18bln dan paling best pharma tak leh kacau sbb dia org tak pegang patent. Malaysia should explore this. |
|
|
|
|
|
|
|
EU pula buat study nak guna ubat anti-malaria untuk lawan Covid-19
|
|
|
|
|
|
|
|
im4me replied at 23-3-2020 09:26 AM
Setakat pengetahuan saya walaupun ''readily'' tetap ada side effect terutama kepada buah pinggang ...
Ada yg organic at 100% purity |
|
|
|
|
|
|
|
im4me replied at 23-3-2020 09:44 AM
mungkin dalam masa yang terdekat negara kita akan cuba..
Im importing it;) |
|
|
|
|
|
|
|
im4me replied at 23-3-2020 09:49 AM
Kayo lah lepas ni....
Aku nak bagi technology ni free kat university pun dia org tak nak...biar jer org sakit dan mati |
|
|
|
|
|
|
|
kod ubat macam nama kereta kebal plak |
|
|
|
|
|
|
|
hanya Toyama Chemical akan mendapat hak pattern selama 5 tahun sebelum boleh diisytihatkan sebagai generik, yang bermakna mereka mempunyai hak khusus untut tujuan Pasaran dalam tempoh berkenaan. kat sini pulak....mamat buncit mano yg dapek
|
|
|
|
|
|
|
|
im4me replied at 23-3-2020 10:14 AM
Biasalah semua benda politik, lagipun system kita banyak menghadkan cerdik pandai untuk menyumbang ...
Jopun kek mano... |
|
|
|
|
|
|
|
im4me replied at 23-3-2020 11:36 AM
dekat dgn Tokyo
Saitama, yokohama, ibaraki? |
|
|
|
|
|
|
|
Edited by mbhcsf at 23-3-2020 12:33 PM
i would be very careful reading this article , if and only if YANG buat press release
a) KKM or Pengarah Kesihatan
b) Pusat Farmasi yg diketua oleh senior experts
c) WHO keluarkan regime
d) Jounals journal dah keluarkan
regime untuk treament sama ada BLIND THERAPY atau DRUGs on TRIAL
itu saja sumber yg saya akan pergi baca.
HARAP KKM atau DG tolong BAGI SEDIKIT KOMEN on the current regime , kalau takmmg ada akan berisko speculation.
So kalau sesiapa PTD MOH ( hehe) atau MOH PR sila panjangkan feedback ini, please.
Thanks
mohon khabarkan yg public seperti saya ingin mengetahui
current regime - sebab ada dah beberapa article sebelum ni pun menyenaraikan blind therapy ..
|
|
|
|
|
|
|
|
Edited by arnauld at 25-3-2020 11:38 AM
im4me replied at 23-3-2020 11:47 AM
Chiba dekat dgn Disneyland
Study ker kerja? Aku prnh stay kat 西船橋 dulu. |
|
|
|
|
|
|
|
im4me replied at 25-3-2020 11:51 AM
Kerja lah aku janggut aku pun dah beruban aku PR Jepun.
Buat apa kat Nishi Funabashi, touri ...
Aku stationed kat hq 東芝 dulu. Dulu Rpkj ker... |
|
|
|
|
|
|
|
Lps aku grad baru ada student med pharmacy ni... |
|
|
|
|
|
|
| |
|